Diversify Advisory Services LLC Purchases Shares of 15,872 TransMedics Group, Inc. $TMDX
Diversify Advisory Services LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 15,872 shares valued at approximately $1.18 million. This acquisition is part of broader institutional investment, with various hedge funds also increasing their stakes in the company, bringing total institutional ownership to 99.67%. Despite strong revenue growth, TransMedics missed earnings estimates for the quarter, and analyst sentiment remains mixed with an average "Hold" rating.
Rosen Law Firm investigates TransMedics Group for possible fiduciary breaches affecting shareholders.
The Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. This action could impact current shareholders of TransMedics stock (TMDX). Investors are encouraged to seek legal representation and gather more information from the firm's website or by contacting them directly.
Summit Creek Advisors LLC Takes $1.77 Million Position in TransMedics Group, Inc. $TMDX
Summit Creek Advisors LLC has acquired a new position in TransMedics Group, Inc. (NASDAQ:TMDX), purchasing 26,707 shares valued at approximately $1.77 million. This makes Summit Creek Advisors LLC the owner of 0.08% of TransMedics Group, with institutional investors collectively holding 99.67% of the stock. Despite reporting strong quarterly revenue growth of 20.7% to $189.95 million, the company missed earnings per share estimates at $0.44 against a $0.50 consensus.
TransMedics Targets $2B Opportunity With Kidney Push, European Expansion
TransMedics Group outlined its growth strategy at a recent conference, focusing on kidney transplantation, European expansion through the PAD Aviation acquisition, and broader adoption of its Organ Care System (OCS) for heart and lung transplants. The company aims for a $2 billion revenue base, with specific targets for 2025 revenue guidance of $737 million to $757 million and an adjusted operating margin near 30% by 2028 or after reaching 10,000 transplants. Its strategy leverages a vertically integrated platform to increase organ availability and improve transplant outcomes, estimating a significant opportunity in the kidney market alone.
TransMedics Group, Inc. Investor News: Rosen Law Firm
The Rosen Law Firm is investigating potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders to visit its website or contact Phillip Kim for more information regarding this investigation. Rosen Law Firm emphasizes its track record of success in investor rights litigation, having recovered billions for investors globally.
TransMedics (TMDX) director gifts 18,000 shares
TransMedics Group, Inc. director James R. Tobin reported a bona fide gift transfer of 18,000 shares of common stock from "The Tobin 2024 Family Trust" on August 17, 2026. Following this transaction, the trust holds 0 shares, while Tobin directly holds 6,981 shares and indirectly holds 155,146 shares through another trust. The filing indicates a neutral impact on the stock as it was a gift, not a sale.
TransMedics Group Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of TransMedics Group, Inc. - TMDX
Kahn Swick & Foti, LLC (KSF) has initiated an investigation into TransMedics Group, Inc. (NasdaqGM: TMDX) regarding potential breaches of fiduciary duties by its officers and directors. This follows a report by Scorpion Capital alleging fraudulent billing, coercive business practices, and unsafe organ transplantation, leading to a securities class action lawsuit against the company. KSF is inviting long-term shareholders to provide information or discuss their legal rights.
Law firm investigates TransMedics officers for possible shareholder duty breaches
Halper Sadeh LLC is investigating whether officers and directors of TransMedics Group, Inc. (TMDX) breached their fiduciary duties to shareholders. Long-term shareholders are encouraged to seek free consultations for potential corporate governance reforms, financial incentives, or other relief. The firm emphasizes the urgency for shareholders to act due to limited time.
TransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Hold" from Brokerages
TransMedics Group, Inc. (NASDAQ:TMDX) has received a consensus "Hold" rating from brokerages, with six analysts recommending "buy," six "hold," and one "sell." The average 12-month price target for the stock is $124.18. The company recently reported quarterly revenue of $189.95 million, exceeding estimates, but its EPS of $0.44 missed the consensus forecast of $0.50.
ETFs Investing in TransMedics Group, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold TransMedics Group, Inc. (TMDX) stocks. The list provides details such as market value, weight of TMDX in the ETF, issuer, management style, focus, expense ratio, AUM, price, change percentage, relative volume, and 3-year NAV total return for each ETF. The ETFs primarily focus on small-cap, extended market, or healthcare sectors.
Transmedics Group Stock Price Forecast. Should You Buy TMDX?
StockInvest.us rates TransMedics Group Inc. (TMDX) as a Buy Candidate with a technical score of 3.67, unchanged from its previous evaluation. The stock has seen an 18.94% gain since its buy signal on July 27, 2026, and is forecasted to rise 20.65% over the next three months. Despite a recent slight dip and increased volume on falling prices, the stock holds short and long-term buy signals from Moving Averages, indicating a positive outlook, though a pivot top sell signal was issued recently.
TransMedics Group, Inc. Investor News: Rosen Law Firm
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm is encouraging shareholders of TransMedics Group to visit its website or contact them for more information regarding this investigation. Rosen Law Firm, known for its work in securities class actions, emphasizes its track record and resources in representing investors globally.
Wasatch Advisors LP Has $20.49 Million Stock Position in TransMedics Group, Inc. $TMDX
Wasatch Advisors LP reduced its stake in TransMedics Group (NASDAQ:TMDX) by 10.9% in the second quarter but still holds 308,434 shares valued at $20.49 million. The company's recent earnings showed a revenue beat but an EPS miss, leading to mixed analyst ratings with an average "Hold" and a target price of $124.18. Institutional investors hold a significant 99.67% of the stock.
ETFs Investing in TransMedics Group, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold stocks of TransMedics Group, Inc. The ETFs are primarily small-cap and health technology focused, providing investors with diversified exposure to the company. The list includes details such as market value, weight of TransMedics stock, issuer, management style, focus, expense ratio, assets under management, price, change, relative volume, and 3-year NAV total return.
TMDX: Strong growth, new kidney program, and global expansion set stage for multi-billion revenue
TransMedics Group, Inc. (TMDX) presented a strong, vertically integrated organ transplant platform demonstrating significant financial growth. The company outlined four major expansion initiatives and a clear strategy to achieve $2–$3 billion in revenue, driven by strategic investments in technology, logistics, and new markets. These efforts are expected to enhance margin improvement and solidify TMDX's industry leadership.
TransMedics Group, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:TMDX)
TransMedics Group, Inc. (TMDX) released its Q2 2026 earnings call presentation, reporting an EPS of $0.44, which missed estimates by $0.04, and revenue of $189.95M, beating estimates by $5.96M with a 20.70% year-over-year increase. The article highlights that the presentation was published in conjunction with their earnings call.
TransMedics Group, Inc. Sued for Securities Law Violations – Investors Should Contact Levi & Korsinsky for More Information - TMDX
A class action securities lawsuit has been filed against TransMedics Group, Inc. (NASDAQ:TMDX) on behalf of investors who suffered losses between February 28, 2023, and January 10, 2025. The lawsuit alleges that TransMedics made false statements and concealed practices such as kickbacks, fraudulent overbilling, coercive tactics, and unsafe practices, which exposed the company to regulatory risk. Levi & Korsinsky, LLP is encouraging affected shareholders to contact them to learn about their rights to seek recovery.
TransMedics Group, Inc. Investor News: Rosen Law Firm
Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders to visit its website or contact them for more information regarding the investigation. Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, with a track record of significant recoveries for investors.
TransMedics Group Inc (TMDX) Stock Up 4.9% and Still Undervalued -- GF Score: 70/100
TransMedics Group Inc (TMDX) shares rose 4.9% to $80.21, but are still estimated to be 48.7% undervalued based on its GF Value™ of $156.29. The stock holds a GF Score™ of 70/100, indicating above-average performance, particularly in growth. However, significant insider selling of $0.7 million and a low valuation rank suggest a potential value trap, prompting caution for investors.
Q2 2026 Transmedics Group Inc Earnings Call Transcript
TransMedics Group Inc (TMDX) reported strong Q2 2026 revenue of ~$190 million, up 21% year-over-year, driven by significant growth in service revenue and logistics market share gains. The company raised its full-year revenue guidance while acknowledging a decline in adjusted operating margin due to increased strategic investments in R&D and clinical programs. Key initiatives include the OCS Kidney program, NextGen platform development, and European expansion through the PAD Aviation acquisition.
TransMedics Group, Inc. Stock 12‑Month Price Target Cut to $97.3, Implies 20% Upside
Analysts have cut the 12-month average price target for TransMedics Group, Inc. (TMDX) stock from $106 to $97.3, which still suggests a 20% upside based on its closing price on August 4th. The consensus rating from 12 analysts remains a "Buy," with 8 recommending Buy and 4 recommending Hold.
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
TransMedics (TMDX) reported a Q2 2026 earnings per share miss of 44 cents, a 52.2% year-over-year decrease, despite revenues rising 20.7% to $189.9 million. The company's shares dropped 7.8% in after-market trading and are down 33.6% year-to-date. Margins contracted due to increased operating expenses, particularly in research and development, although TransMedics raised the lower end of its full-year 2026 revenue guidance.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages TransMedics shareholders to visit its website for more information or contact them directly. Rosen Law Firm specializes in securities class actions and shareholder derivative litigation, with a history of successful settlements for investors.
TransMedics Group Q2 Earnings Call Highlights
TransMedics Group reported record second-quarter revenue of approximately $190 million, driven by growth in liver procedures, clinical services, and transplant logistics. The company is prioritizing long-term growth by investing in expanding heart and lung adoption, developing its OCS Kidney platform, building a European logistics network, and advancing its next-generation OCS Gen 3.0 platform. While increasing its full-year 2026 revenue outlook, TransMedics lowered its margin outlook due to accelerated investment in OCS Kidney.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. - TMDX
The Rosen Law Firm has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). Investors who own shares of TransMedics Group stock are encouraged to visit the firm's website or contact them for more information regarding this investigation. The firm, known for its focus on securities class actions and shareholder derivative litigation, encourages investors to select experienced counsel.
TransMedics Stock Dips Post Q2 Earnings Miss, Margins Contract
TransMedics (TMDX) reported a Q2 2026 earnings per share miss of 44 cents, a 52.2% year-over-year decrease, despite revenues rising 20.7% to $189.9 million, surpassing estimates. The company's gross margin contracted, and operating expenses significantly increased due to investments in clinical programs and product development. TransMedics raised the lower end of its 2026 revenue guidance but expects a lower adjusted operating margin due to accelerated OCS Kidney investments.
UBS Adjusts Price Target on TransMedics Group to $77 From $80, Maintains Neutral Rating
UBS has revised its price target for TransMedics Group (TMDX) down to $77 from $80, while maintaining a "Neutral" rating on the stock. This adjustment comes after the company reported its Q2 2026 earnings, where adjusted net income fell despite a rise in revenue. The report also highlights recent financial performance and analyst actions for TransMedics Group.
TransMedics Group (TMDX) Stock Rises on Q2 2026 Earnings
TransMedics Group (TMDX) reported Q2 2026 revenue of $189.9 million, exceeding estimates, which led to a 9.62% rise in share price after market close. Despite revenue growth, profitability decreased, with operating profit down 35.1% and net income down 57.9%. The article also details recent insider selling activity, hedge fund movements, and current analyst price targets for TMDX.
TRANSMEDICS GROUP, INC. : CANACCARD GENUITY CUTS TARGET PRICE TO $95 FROM $124
Canaccord Genuity has reduced its target price for TransMedics Group, Inc. (TMDX.O) from $124 to $95. This information was reported by Reuters on August 5, 2026. The article advises readers that its content reflects only the author's opinion and should not be used as investment advice.
TransMedics Group Q2 Earnings Call Highlights
TransMedics Group reported record Q2 revenue of $190 million, up 21% year over year, driven by strong liver and logistics growth. Despite this, the company lowered its full-year adjusted operating margin outlook to 12.5%-14% due to significant investments in heart and lung adoption, OCS Kidney development, European expansion, and its next-generation platform. TransMedics raised its full-year revenue forecast to $737 million to $757 million, excluding PAD Aviation, which will initially dilute margins upon consolidation in Q3.
TransMedics Group (NASDAQ:TMDX) Posts Earnings Results, Misses Expectations By $0.06 EPS
TransMedics Group (NASDAQ:TMDX) announced its quarterly earnings, reporting $0.44 EPS, which missed analyst expectations by $0.06, despite revenue of $189.95 million exceeding estimates. The company's shares fell 1.0% to $80.75 following the announcement. Analysts have a mixed view, with an average "Hold" rating and a consensus price target of $126.27.
TransMedics Group (TMDX) Stock Looks Cheap On Earnings But Full After 171% Gain
TransMedics Group (TMDX) has seen a 170.9% gain over five years, yet valuation tests suggest its stock is currently undervalued at US$80.75. The stock trades at a P/E ratio of 16.2x, significantly below the Medical Equipment industry average of 31.9x and its own tailored fair P/E of 24.9x, indicating a potential market discount. The article explores bull and bear cases for TMDX, focusing on its recurring revenue model potential versus healthcare cost and competitive pressures.
TransMedics Group, Inc. Q2 2026: Revenue $189.9M, EPS $0.41— 10-Q Summary
TransMedics Group, Inc. reported its Q2 2026 financial results, showing revenue of $189.9 million, a 20.7% increase year-over-year, primarily driven by OCS Liver sales and NOP service usage. Despite revenue growth, net income declined by 57.9% to $14.7 million, resulting in a diluted EPS of $0.41 compared to $0.92 in the prior year. The company expanded its operational scale, including investments in R&D, clinical trials, and infrastructure, with a channel shift toward recurring service revenue impacting gross margin.
TransMedics Reports Second Quarter 2026 Financial Results
TransMedics Group, Inc. announced strong financial results for the second quarter of 2026, with total revenue reaching $189.9 million, a 21% increase year-over-year. The company reported a net income of $14.7 million ($0.41 per diluted share) and raised the low end of its full-year 2026 revenue guidance to $737 million to $757 million. This growth was primarily driven by increased utilization of its Organ Care System (OCS) and logistics services, alongside a strategic investment in PAD Aviation to establish an organ transplantation air logistics network in Europe.
Do TransMedics’ (TMDX) New Equity Grants And UBS Coverage Reveal A Shifting Growth Playbook?
TransMedics Group (TMDX) announced Q2 2026 financial results, new equity grants to employees, and received fresh UBS research coverage with an $80 price target and Neutral rating. These developments suggest a shifting focus towards internal talent incentives and external analyst attention as the company enters its next growth phase. Investors are now watching how upcoming results will either justify current optimism or highlight potential risks related to margins and regulatory scrutiny.
Bronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of investors who purchased TransMedics Group, Inc. (TMDX) securities prior to February 3, 2022, and continue to hold them. The investigation seeks to determine if TransMedics and its officers engaged in corporate wrongdoing. The firm encourages affected investors to connect with them to assist in the investigation, operating on a contingency fee basis.
TransMedics Group, Inc. $TMDX Shares Bought by First Trust Advisors LP
First Trust Advisors LP significantly increased its stake in TransMedics Group, Inc. by 111.5% in the first quarter, now owning 53,889 shares valued at $5,357,000. Several other institutional investors also expanded their positions, bringing total institutional and hedge fund ownership to 99.67%. Despite this increased ownership, TransMedics' recent quarterly earnings missed analyst expectations for EPS, and the stock has received cautious ratings from analysts.
TransMedics Group, Inc. Investor News: Rosen Law Firm Announces Investigation of Breaches of Fiduciary Duties by the Directors and Officers of TransMedics Group, Inc. – TMDX
Rosen Law Firm, a global investor rights law firm, has announced an investigation into potential breaches of fiduciary duties by the directors and officers of TransMedics Group, Inc. (NASDAQ: TMDX). The firm encourages current shareholders of TransMedics Group to visit its website or contact them for more information regarding this investigation. Rosen Law Firm emphasizes its track record in securities class actions and shareholder derivative litigation, having recovered billions for investors.
TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
TransMedics Group, Inc. announced the grant of non-qualified stock options and restricted stock units to nine new employees as a material inducement for their employment. These grants, totaling 18,762 shares in stock options and 12,414 restricted stock units, were approved by the Compensation Committee and comply with Nasdaq Listing Rule 5635(c)(4). The stock options have an exercise price of $78.00 and vest over four years, while the restricted stock units also vest over four years, both subject to continued employment.
TransMedics Grants Stock Awards to 9 Employees Joining Company
TransMedics (Nasdaq: TMDX) announced it granted stock options for 18,762 shares and 12,414 restricted stock units to nine new employees on July 29, 2026. These awards serve as material inducements for employment under its Inducement Plan and Nasdaq Listing Rule 5635(c)(4). The stock options have a 10-year term with an exercise price of $78.00, vesting over four years, while RSUs also vest over four years, both subject to continued service.
TMDX Maintained by Needham -- Price Target Lowered to $106.00
Needham has maintained a 'Buy' rating on TransMedics Group (TMDX) but lowered its price target from $142.00 to $106.00, reflecting a 25.35% decrease and a more cautious outlook. Despite this, GuruFocus indicates TMDX is 55.4% undervalued, with strong growth potential but challenges in profitability and valuation. Insider activity shows net selling, suggesting some caution among insiders regarding near-term prospects.
TransMedics Group Jumps 7.5% After UBS Initiates at Neutral
TransMedics Group's stock surged 7.5% after UBS initiated coverage with a Neutral rating and an $80 price target. Despite the cautious rating, the market viewed the initiation as validation, pushing the stock to $82.22, above the analyst's target. Investors will monitor future analyst coverage and operational updates to see if this momentum is sustained.
TransMedics Group, Inc. $TMDX Shares Bought by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its stake in TransMedics Group Inc. by 5.5% in the first quarter, bringing its total holdings to 516,679 shares valued at approximately $51.4 million. Despite a 21.2% year-over-year revenue increase to $173.93 million, the company missed analyst EPS estimates in Q1. Institutional investors own 99.67% of the company, and analyst sentiment is mixed, with an average "Hold" rating and a price target of $129.55.
Militia Capital Management LLC Purchases Shares of 21,000 TransMedics Group, Inc. $TMDX
Militia Capital Management LLC recently acquired 21,000 shares of TransMedics Group, Inc. worth approximately $2.09 million. The company's stock, trading under NASDAQ:TMDX, currently holds a consensus "Hold" rating from analysts with an average price target of $129.55, despite missing recent quarterly earnings estimates. Institutional investors collectively own 99.67% of the company's stock.
(TMDX) Risk Channels and Responsive Allocation
This article provides an AI-driven analysis of Transmedics Group Inc. (NASDAQ: TMDX), highlighting a potential shift in near-term positive sentiment and a mid-channel oscillation pattern. It identifies an exceptional short setup with a significant risk-reward ratio and outlines three distinct trading strategies: a position trading strategy, a momentum breakout strategy, and a risk hedging strategy, each tailored for different risk profiles and holding periods. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
TransMedics Group, Inc. Revenue Breakdown – MIL:1TMDX
TransMedics Group, Inc. (1TMDX) generated 515.53 million EUR in revenue last year. The Liver Organ Care System segment was the top performer, contributing 392.10 million EUR, an increase from the previous year. The United States was the largest regional contributor, accounting for 497.82 million EUR of the company's revenue.
Price to earnings forward of TransMedics Group, Inc. – NASDAQ:TMDX
This page provides financial data for TransMedics Group, Inc. (NASDAQ: TMDX), specifically focusing on its forward price-to-earnings ratio. It highlights that the information is "Made by humans" and sources its market and reference data from ICE Data Services and FactSet, respectively. The content appears to be a financial data page from TradingView, focusing on a specific metric for the company.
TMDX|Transmedics Group Inc|Price:78.040|Chg%:+1.750
This article provides a comprehensive stock analysis of Transmedics Group Inc (TMDX) by TradingKey, assigning it a positive score for fundamental health and growth potential while noting its fair valuation. It highlights the company's strengths in organ transplant technology, high institutional ownership, and a "Buy" rating from multiple analysts, despite a projected medium-term downward trend for the stock price. The analysis also details how its proprietary Stock Score is generated across various dimensions like financial health, valuation, earnings forecasts, price momentum, institutional confidence, and risk assessment.
ETFs Investing in TransMedics Group, Inc. Stocks
This article lists numerous Exchange Traded Funds (ETFs) that hold TransMedics Group, Inc. (TMDX) stocks, providing detailed information such as market value, weight, issuer, management style, and expense ratios for each fund. The funds are primarily focused on small-cap, extended market, and healthcare sectors, making them accessible investment options with diversified opportunities for investors interested in TMDX.
TransMedics to present at Canaccord Genuity Growth Conference on Aug 11, showcasing organ transplant tech. TMDX $76.26 +$1.98 +2.67%
TransMedics Group, a leader in organ transplant technology, announced it will present at the Canaccord Genuity 46th Annual Growth Conference in Boston on August 11, 2026. The company specializes in portable organ preservation and assessment devices that improve transplant outcomes for heart, lung, and liver failure patients. This event will provide insights into their innovations and growth prospects and highlights their efforts to enhance organ transplant success.
